Ascendis Pharma has been added to the Russell 3000, Russell 1000, Russell 2500, and Russell Midcap indexes as part of the 2026 semi-annual reconstitution. This inclusion reflects the company's growing market capitalization and increases its visibility among investors, as these indexes are widely used benchmarks for investment funds and strategies. The move may attract more institutional investment and supports Ascendis Pharma's profile in the U.S. equity market. The company continues to focus on developing innovative therapies using its TransCon technology platform.

More News (ASND)

Ascendis Pharma reveals positive trial data for achondroplasia treatments at ICCBH 2026.

Ascendis Pharma announced new clinical data on its treatments for children with achondroplasia, presented at ICCBH 2026. The data show improvements in lower-extremity alignment and skeletal dysplasia symptoms from their TransCon CNP and combination t...

Market News

Bullish

1 day ago

Ascendis Pharma joins multiple Russell U.S. indexes, boosting its market visibility.

More News (ASND)

Ascendis Pharma reveals positive trial data for achondroplasia treatments at ICCBH 2026.

Invest & Trade with
#1 Award-Winning Investment Super App

Invest

Features

Fees

Learn

Investment Clubs (Coming Soon)

Support

iOS App Store

Google Play Store

Ascendis Pharma joins multiple Russell U.S. indexes, boosting its market visibility.

More News (ASND)

Ascendis Pharma reveals positive trial data for achondroplasia treatments at ICCBH 2026.

Invest & Trade with#1 Award-Winning Investment Super App

iOS App Store

Google Play Store

Invest & Trade with
#1 Award-Winning Investment Super App